Participants and treatment
As of July 17, 2020, median (range) duration of follow-up was 8.4 (0.1–25.7) months for the 34 patients who received GCb alone, 14.0 (1.3–33.6) months for the 33 patients who received trilaciclib prior to GCb on days 1 and 8, and 15.3 (3.5–33.7) months for the 35 patients who received trilaciclib alone on days 1 and 8 and trilaciclib prior to GCb on days 2 and 9. Antitumor response status was available for 58 of the 68 patients who received trilaciclib prior to GCb: 27 patients (46.6%) had an antitumor response with trilaciclib plus GCb (trilaciclib responders), and 31 (53.4%) had no response (non‑responders).